Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Drug Profile

Research programme: gene therapies for CNS disorders - Voyager Therapeutics

Alternative Names: AAV-delivered gene therapies for CNS disorders - Voyager Therapeutics; AAVrh.10-vectored PHF1; Amyotrophic lateral sclerosis gene therapy - Voyager Therapeutics; Friedreich’s ataxia gene therapy - Voyager Therapeutics; Huntington's disease gene therapy - Voyager Therapeutics; VY FXN01; VY HTT01; VY SMN101; VY SOD101; VY-NAV01; VY-TAU01

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Voyager Therapeutics
  • Class Analgesics; Gene therapies; Monoclonal antibodies
  • Mechanism of Action Gene transference; Nav1.7-voltage-gated-sodium-channel-inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Friedreich's ataxia; Huntington's disease; Pain; Spinal muscular atrophy

Most Recent Events

  • 01 Jun 2017 Pharmacodynamics and safety data from preclinical study in Huntington’s Disease released by Voyager Therapeutics
  • 15 Mar 2017 Voyager Therapeutics announces intention to submit IND for VY FXN01 for Friedreich’s ataxia
  • 15 Mar 2017 Voyager Therapeutics announces intention to submit IND for VY HTT01 for Huntington’s disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top